Two autologous chimeric antigen receptor (CAR) T cell therapies (Kymriah™ and 
Yescarta™) were recently approved by the FDA. Kymriah™ is for the treatment of 
pediatric patients and young adults with refractory or relapse (R/R) B cell 
precursor acute lymphoblastic leukemia and Yescarta™ is for the treatment of 
adult patients with R/R large B cell lymphoma. In common, both are CD19-specific 
CAR T cell therapies lysing CD19-positive targets. Their dramatic efficacy in 
the short term has been highlighted by many media reports. By contrast, their 
glaring safety gaps behind the miracles remain much less addressed. Here, we 
focus on addressing the crucial challenges in relation to the gaps.